SPOTLIGHT: Special Report: 2007 FDA approvals

As has been pointed out on many occasions, 2007 was a lean year for new drug approvals. The FDA approved only 15 new molecular entities (NMEs) last year--17 if you include two new biologics (Soliris and Mircera) OK'd by CDER. Here's a look at the drugs that made it through the rigorous review process and earned FDA approval in 2007. List

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.